26 February 2025
Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment
Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel...
25 February 2025
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market (the “Agreement”) with Venus Remedies Ltd (NSE: VENUSREM BSE: 526953) (“Venus Remedies”), an Indian...
18 February 2025
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that in collaboration with Justus-Liebig-University Giessen (“JLU”), Germany it has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), to...
17 February 2025
Manchester medtech company Pill Connect secures new investment to transform clinical trials
A medtech company that has created a unique digital device to track whether patients are taking their medicine correctly has secured funding from the GMC Life Sciences Fund By Praetura, and through NPIF II – Praetura Equity Finance, which is managed by Praetura Ventures as part...
12 February 2025
AgTech startup CroBio raises €850k to reshape agriculture through enhanced microbes
Cheshire-based CroBio, an AgTech startup on a mission to reshape the future of agriculture by harnessing the power of enhanced microbes, announced €805k in new funding to enhance their living soil amendment, a technology designed to improve nutrient retention, water retention...
21 January 2025
Monument Therapeutics announces grant of Chinese patent in support of its MT1988 cognitive impairment associated with schizophrenia program.
Manchester, UK, 21 January 2025 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted Chinese...
14 January 2025
Monument Therapeutics announces grant of Japanese patent in support of its MT1988 cognitive impairment associated with schizophrenia program
Manchester, UK, 14 January 2025 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of...
13 January 2025
Boehringer Ingelheim acquires fourth license for the development of novel antibody based cancer treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has exercised an option for...
7 January 2025
Maxwellia announces strategic leadership appointments to propel future growth
Alderley Park, Cheshire, UK – Monday 6 January 2025 – Maxwellia, the female founded pioneering consumer healthcare company, is pleased to announce two significant additions to its leadership team. Candice Brett has been appointed as Chief Financial Officer (CFO), and Colin...
27 November 2024
Maxwellia launches unexpected menstrual health campaign following concerning survey results
• New survey released today reveals 56% of people feel unsure about the phases of the menstrual cycle … • 66% of participants said they lacked confidence in explaining the hormonal changes that occur during the different phases of the cycle … • Heavy period brand, Evana® creates...